Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FLOX + Cetuximab (Erbitux®): First Line Treatment for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor, A Phase II Study

NCT00660582 is registered in ClinicalTrials.gov with Per Pfeiffer as lead sponsor.

NCT NCT00660582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00660582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FLOX + Cetuximab (Erbitux®): First Line Treatment for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor, A Phase II Study
Lead sponsor
Per Pfeiffer
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2008
Completion date
February 28, 2013
Enrollment
152 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer